Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hyperuricemia 5Tumor Lysis Syndrome 4Lymphoma 4Leukemia 4Neoplasms 2Burkitt Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nutritional and Metabolic Diseases 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Urate Oxidase × Clear all
NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡